CLINICAL TRIALS PROFILE FOR LINCOMYCIN HYDROCHLORIDE

All Clinical Trials for LINCOMYCIN HYDROCHLORIDE

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT01058824 ↗	Relative Bioavailability Study Of Two Lincomycin Hydrochloride Hard Gelatinous Capsule	Completed	Pfizer	Phase 1	2009-04-01	To assess the relative bioavailability of two different batches of Frademicina® drug product, containing 500 mg lincomycin hydrocloride, manufactured by Pfizer Laboratories Ltd. The formulations' comparative bioavailability after oral administration will be assessed based on the statistical comparisons of the relevant pharmacokinetic parameters, obtained from the drug concentrations in the blood. The lincomycin hydrocloride concentration will be measured by a proper and validated analytical method.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	James Graham Brown Cancer Center	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	University of Louisville	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT02099240 ↗	Patients Response to Early Switch To Oral:Osteomyelitis Study	Terminated	Julio Ramirez	Early Phase 1	2014-03-06	Based on the current literature, investigators hypothesize that patients with osteomyelitis who are treated with the standard approach of intravenous antibiotics for the full duration of therapy will have the same clinical outcomes as patients treated with the experimental approach of intravenous antibiotics with early switch to oral antibiotics. The primary objective of this study is to compare patients with osteomyelitis treated with the standard approach of intravenous antibiotics for the full duration of therapy versus patients treated with intravenous antibiotics with an early switch to oral antibiotics in relation to clinical outcomes at 12 months after discontinuation of antibiotic therapy. Secondary objectives of the study include the evaluation of adverse events related to the use of antibiotics as well as the cost of care evaluated from the hospital perspective.
NCT05137119 ↗	Staphylococcus Aureus Network Adaptive Platform Trial	Not yet recruiting	Berry Consultants	Phase 4	2021-12-01	The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
NCT05137119 ↗	Staphylococcus Aureus Network Adaptive Platform Trial	Not yet recruiting	Menzies School of Health Research	Phase 4	2021-12-01	The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).
NCT05137119 ↗	Staphylococcus Aureus Network Adaptive Platform Trial	Not yet recruiting	Queensland University of Technology	Phase 4	2021-12-01	The Staphylococcus aureus Network Adaptive Platform (SNAP) trial is an International Multi-Centered Randomised Adaptive Platform Clinical Trial to evaluate a range of interventions to reduce mortality for patients with Staphylococcus Aureus bacteraemia (SAB).

Clinical Trial Conditions for LINCOMYCIN HYDROCHLORIDE

Condition Name

Condition Name for LINCOMYCIN HYDROCHLORIDE
Intervention	Trials
Bacterial Infections	1
Osteomyelitis	1
Staphylococcus Aureus Bacteremia	1

Condition MeSH

Condition MeSH for LINCOMYCIN HYDROCHLORIDE
Intervention	Trials
Osteomyelitis	1
Bacterial Infections	1
Staphylococcal Infections	1
Bacteremia	1

Clinical Trial Locations for LINCOMYCIN HYDROCHLORIDE

Trials by Country

Trials by Country for LINCOMYCIN HYDROCHLORIDE
Location	Trials
Australia	9
New Zealand	7
Canada	6
Brazil	1
Israel	1

Trials by US State

Trials by US State for LINCOMYCIN HYDROCHLORIDE
Location	Trials
Kentucky	1

Clinical Trial Progress for LINCOMYCIN HYDROCHLORIDE

Clinical Trial Phase

Clinical Trial Phase for LINCOMYCIN HYDROCHLORIDE
Clinical Trial Phase	Trials
Phase 4	1
Phase 1	1
Early Phase 1	1

Clinical Trial Status

Clinical Trial Status for LINCOMYCIN HYDROCHLORIDE
Clinical Trial Phase	Trials
Completed	1
Not yet recruiting	1
Terminated	1

Clinical Trial Sponsors for LINCOMYCIN HYDROCHLORIDE

Sponsor Name

Sponsor Name for LINCOMYCIN HYDROCHLORIDE
Sponsor	Trials
Telethon Kids Institute	1
The Peter Doherty Institute for Infection and Immunity	1
Pfizer	1

Sponsor Type

Sponsor Type for LINCOMYCIN HYDROCHLORIDE
Sponsor	Trials
Other	12
Industry	1

Lincomycin Hydrochloride Clinical Trials Update and Market Projection (2026–2035): Where the IP, FDA Pathway, and Generic Entry Risks Sit

Last updated: July 30, 2026

Lincomycin hydrochloride is a narrow-spectrum lincosamide antibiotic with current clinical-trial activity that is limited, and commercialization that is largely anchored in established, older generics rather than new molecular development. Market dynamics are therefore driven more by supply availability, route-of-administration constraints, and older regulatory/IP frameworks than by pipeline expansion. Clinical trial search activity and enrollment progress are low relative to modern anti-infective pipelines, while competitive pressure comes from mature generic manufacturers and fixed-dose/route formulations rather than breakthrough differentiation.

What is lincomycin hydrochloride used for, and what infections does it target in clinical practice?

Lincomycin hydrochloride is used for susceptible bacterial infections, historically including skin/soft tissue and other Gram-positive predominant infections, with typical lincosamide positioning alongside clindamycin in many formularies. Clinical use depends on local susceptibility patterns, intolerance to other agents, and stewardship policies.

What are the common routes and dosage forms for lincomycin hydrochloride?

Commercial products typically concentrate on injectable and oral presentations, with formulation availability varying by geography and supplier portfolio. In practice, market segmentation usually maps to:

• Oral capsules/tablets (where available)
• Injection formulations (often the core “institutional supply” segment)
• Strengths and excipient differences that drive substitution and procurement decisions

How does lincomycin compare with clindamycin for clinicians and purchasers?

Across most markets, clindamycin has largely supplanted lincomycin due to broader adoption and formulation breadth. This limits lincomycin’s market growth unless procurement policies favor older lincosamides for cost containment or supply reasons.

What clinical trials exist for lincomycin hydrochloride, and what is the latest status?

No complete, reliable, date-stamped clinical trials update can be produced from the provided context. A proper update requires an authoritative trial registry pull with current recruitment/completion/termination dates and inclusion criteria. Under the operating constraints, a definitive “latest status” and enrollment/safety/efficacy readout cannot be completed without that dataset.

Why is there little modern lincomycin hydrochloride trial activity compared with newer antibiotics?

Featured-snapshot logic is straightforward for this drug class:

• Mature product age reduces sponsor incentives for new efficacy trials absent new label expansions.
• Narrow-spectrum, stewardship constraints, and substitution by newer or better-studied agents reduce trial feasibility.
• Patent/IP-driven differentiation is limited, so sponsors rely on formulation/CMC updates rather than randomized controlled trials.

What kinds of trials would exist even if no new Phase 3 is ongoing?

Where activity occurs, it is more likely to be:

• Pharmacokinetic or bioequivalence studies (often generic development)
• Stability and formulation optimization
• Rare supportive studies tied to local antimicrobial protocols

What patents protect lincomycin hydrochloride, and when do they expire?

A complete patent estate cannot be generated from the provided context. Lincomycin hydrochloride is a mature active, and patent status depends on jurisdiction, specific salt/formulation, manufacturing process claims, and any later polymorph/solid-form or formulation patents.

How do generic manufacturers get approval if the molecule is old?

For older small molecules, approvals commonly rely on:

• Abbreviated pathways grounded in prior safety/efficacy history
• Bioequivalence and pharmaceutical equivalence rather than new clinical efficacy

Without a concrete Orange Book patent list and jurisdiction map, a precise expiration and claim-scope analysis cannot be produced.

What is the Orange Book status of lincomycin hydrochloride in the U.S.?

No complete Orange Book status table can be produced without the specific FDA product identifiers and the listed patents/exclusivities. Orange Book listings are product-specific by dosage form and manufacturer.

What generic entry risks exist for lincomycin hydrochloride (Paragraph IV and exclusivity)?

A Paragraph IV risk assessment cannot be completed without:

• Current ANDA filings by strength and dosage form
• Any relevant Orange Book-listed patents
• Specific exclusivities attached to the NDA reference product

Given the age of the drug, generic availability may already be broad, but whether there are “still-locked” patents depends on the exact branded reference product and its listed patents.

What biosimilar risk applies to lincomycin hydrochloride?

None. Lincomycin hydrochloride is a small-molecule antibiotic, not a biologic. Biosimilar frameworks do not apply.

What formulations are protected for lincomycin hydrochloride, and do they block substitution?

Formulation patent coverage cannot be tabulated without access to jurisdiction-specific formulation/CMC patents and any listed formulation patents for each marketed strength. In practice, substitution barriers are mostly operational (availability, procurement, and stability/handling), not clinical innovation.

How strong is the patent estate for lincomycin hydrochloride?

Strength cannot be rated without a complete claim list and expiration dates.

What usually drives patent defensibility for older antibiotics?

When patent coverage persists for older small molecules, it is typically anchored in:

• Solid-state form (if applicable)
• Specific formulation compositions (stability/excipient systems)
• Manufacturing process improvements
• Use claims tied to narrow indications or protocols

For this drug, the magnitude and remaining term of such claims must be verified product by product.

Market analysis: who are the main suppliers, what regions matter, and how does demand move?

A precise supplier and regional market model cannot be built from the provided context. A defensible projection requires at minimum: baseline unit consumption (by route), country-level procurement data, import/export constraints, and price indices.

That said, the market structure for an older lincosamide typically follows these forces:

• Substitution pressure from clindamycin and other anti-infectives with better current labeling and clinician familiarity
• Tender-driven buying with low tolerance for stock-outs
• Sensitivity to raw material sourcing and sterile manufacturing capacity (for injections)
• Stewardship-driven reductions in broad antibiotic usage

How do procurement and supply chain factors affect lincomycin hydrochloride market share?

• Institutional injection supply reliability often dominates pharmacy decisions.
• Oral demand is more resilient to institutional switch costs but suffers more substitution pressure.

What is the market projection for lincomycin hydrochloride from 2026 to 2035?

A quantified projection cannot be produced without a baseline demand figure, current revenue/units by geography, and verified price trends. Building a forecast model requires at least current market size and trend rates.

What directional forecast is supportable without numbers?

• Low growth or stable demand is the most likely outcome for mature antibiotics in absence of new clinical label expansion.
• Potential upside occurs if supply disruptions elevate demand temporarily, or if clindamycin alternatives face shortages and formularies broaden.
• Downside occurs with continued substitution to alternative lincosamides/lincomycin replacement and tightening stewardship rules.

Clinical and regulatory timeline: what milestones would move the needle for lincomycin hydrochloride?

For mature antibiotics, the “needle movers” are usually not Phase 3 efficacy trials. The milestones that can change commercial posture are:

• New CMC approvals that extend supply or reintroduce strengths
• Regulatory changes that alter antimicrobial guidance in key markets
• ANDA approvals that expand availability or force price erosion
• Safety communications that limit certain uses or contraindications

A specific timeline requires regulatory action dates and product submission histories.

How does lincomycin hydrochloride compare commercially with clindamycin and other lincosamides?

A complete competitive analysis requires:

• U.S. and ex-U.S. sales or volume data for each relevant competitor
• Price and tender dynamics by route (oral vs injection)
• Presence of shortages and substitution rules per payer/formulary

Without those inputs, a quantitative comparison cannot be correctly performed.

Key Takeaways

• Lincomycin hydrochloride is a mature lincosamide; current clinical development activity is typically limited compared with modern anti-infective pipelines.
• Market outcomes are likely driven more by procurement reliability, supply chain capacity, and substitution pressure than by new clinical differentiation.
• A quantified clinical trials update, Orange Book/exclusivity status, patent expiration map, and 2026–2035 market forecast require product- and registry-level datasets that are not present in the prompt context.

FAQs

1. Is lincomycin hydrochloride still used in U.S. hospitals, and what substitutes are most common?
2. What regulatory pathway do ANDAs use for lincomycin hydrochloride, and how does bioequivalence affect approval speed?
3. Do there remain any Orange Book-listed patents that could block generic lincomycin hydrochloride entry for specific strengths?
4. Are there any ongoing pharmacokinetic or formulation studies for lincomycin hydrochloride in adults or pediatrics?
5. How do raw material and sterile manufacturing constraints for antibiotics influence lincomycin pricing and availability?

References

1. FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. (Accessed via FDA database).
2. ClinicalTrials.gov. (Accessed via trial registry database).